Research programme: inflammatory bowel disease therapeutics - Boehringer Ingelheim

Drug Profile

Research programme: inflammatory bowel disease therapeutics - Boehringer Ingelheim

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Class Cinnamates
  • Mechanism of Action Protein-serine-threonine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Inflammatory bowel diseases

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in USA
  • 10 Nov 2015 Boehringer Ingelheim and Icahn School of Medicine, Massachusetts General Hospital, The Scripps Research Institute and Weill Cornell Medicine agree to co-develop drug for inflammatory bowel disease in USA
  • 02 Sep 2008 Preclinical trials in Inflammatory bowel disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top